EUVIMEDEUVIMED entdecken
Crossref

Liver‐Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction

Li-You Lian, Tianyi Xia, Zhong-Wei Chen, Cai-Yun Wen, Xiao-Dong Zhou iD, Tie Xiao, Giovanni Targher iD, Christopher D Byrne, Yee Hui Yeo iD, Shenghong Ju, Wen-Yue Liu, Ming-Hua Zheng iD

Liver International · 2026-03 · 46 (3)

DOI: 10.1111/liv.70548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 14.02.2026. Verfasst von Li-You Lian und 11 weiteren Autor:innen. Beteiligte Einrichtung: MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Pancreatic Diseases, Liver, Non-alcoholic Fatty Liver Disease, Pancreas. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) and pancreatic steatosis (PS) are interconnected ectopic fat conditions linked to cardiometabolic dysregulation. Their combined effect on the long‐term risk of cardiometabolic multimorbidity (CMM; ≥ 2 of diabetes, hypertension, coronary heart disease, and stroke) and cardiac remodelling remains unclear.

Methods

We examined cross‐sectional associations between PS and the severity of MASLD histology in a biopsy‐proven MASLD cohort from China. Subsequently, using the UK Biobank, we assessed the long‐term risk of developing both incident CMM and cardiac structural/functional alterations (via cardiac magnetic resonance [CMR]) associated with single‐organ versus dual‐organ steatosis. Exploratory proteomic profiling was performed to identify potential molecular pathways.

Results

In the biopsy‐proven cohort ( n = 482), both continuous pancreatic proton density fat fraction and PS status were associated with severe hepatic steatosis, lobular inflammation, and fibrosis (all p < 0.05). In the UK Biobank cohort ( n = 16 408; median follow‐up of 5.6 years), the coexistence of MASLD and PS additively increased the risk of new‐onset CMM (HR = 2.013, 95% CI: 1.219–3.322, p = 0.006). Dual‐organ steatosis was also associated with marked cardiac alterations, specifically increased left ventricular mass and impaired ventricular function. Proteomics revealed upregulation of lysosomal catabolic and glycosaminoglycan‐degrading pathways in dual‐organ steatosis compared to single‐organ steatosis. Gene Ontology highlighted heparan sulphate proteoglycan catabolism as a hallmark of dual‐organ involvement.

Conclusion

PS is associated with greater severity of MASLD histology, and the concomitant involvement of both the liver and pancreas drives a higher risk of CMM and cardiac remodelling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic DiseasesLiverNon-alcoholic Fatty Liver DiseasePancreasFatty LiverHumansFemaleMaleCross-Sectional StudiesMiddle AgedChinaUnited KingdomAdultProteomicsMagnetic Resonance ImagingAged

Stichwörter der Autor:innen

cardiac magnetic resonancecardiometabolic multimorbiditymetabolic dysfunction‐associated steatotic liver diseasepancreatic steatosisproton density fat fraction

Autor:innen und Institutionen

  • MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Institute of Hepatology, Wenzhou Medical University, Wenzhou, China.
  • Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
  • Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Chin…
  • Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Medicine, University of Verona, Verona, Italy.

ORCID-Profile: Xiao-Dong Zhou, Giovanni Targher, Yee Hui Yeo, Ming-Hua Zheng

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Lian, L. Y., Xia, T., Chen, Z. W., Wen, C. Y., Zhou, X. D., Xiao, T., Targher, G., Byrne, C. D., Yeo, Y. H., Ju, S., Liu, W. Y., & Zheng, M. H. (2026). Liver‐Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction. Liver International, 46(3). https://doi.org/10.1111/liv.70548

Vancouver

Lian LY, Xia T, Chen ZW, Wen CY, Zhou XD, Xiao T, et al. Liver‐Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction. Liver International. 2026;46(3). doi:10.1111/liv.70548

BibTeX
@article{Lian2026,
  author = {Lian, Li-You and Xia, Tianyi and Chen, Zhong-Wei and Wen, Cai-Yun and Zhou, Xiao-Dong and Xiao, Tie and Targher, Giovanni and Byrne, Christopher D and Yeo, Yee Hui and Ju, Shenghong and Liu, Wen-Yue and Zheng, Ming-Hua},
  title = {Liver‐Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1111/liv.70548}
}
Kostenlos starten →